The efflux transporters ABCB1 and ABCG2 have been demonstrated to interact with tyrosine kinase inhibitors (TKIs) such as dasatinib, and to reverse drug-resistance in human multidrug-resistant multiple myeloma cells mediated by Src inhibition [66]. Here, SRC is linked to plasma cell myeloma.